David A Scheinberg

List of Publications by Year
in descending order

81 papers	4,725 citations	159585 30 h-index	102487 66 g-index
85 all docs	85 docs citations	85 times ranked	8012 citing authors

#	Article	IF	Citations
1	Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood, 2011, 118, 4817-4828.	1.4	1,135
2	Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. Genome Biology, 2016, 17, 231.	8.8	746
3	Acute myeloid leukaemia. Nature Reviews Disease Primers, 2016, 2, 16010.	30.5	277
4	Conscripts of the infinite armada: systemic cancer therapy using nanomaterials. Nature Reviews Clinical Oncology, 2010, 7, 266-276.	27.6	173
5	Targeting the Intracellular WT1 Oncogene Product with a Therapeutic Human Antibody. Science Translational Medicine, 2013, 5, 176ra33.	12.4	147
6	Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1. Nature Biotechnology, 2015, 33, 1079-1086.	17.5	134
7	Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells. Cancer Immunology Research, 2016, 4, 936-947.	3.4	132
8	Actinium-225 in Targeted Alpha-Particle Therapeutic Applications. Current Radiopharmaceuticals, 2011, 4, 306-320.	0.8	126
9	Nontranscriptional Role of Hif-1Î± in Activation of Î³-Secretase and Notch Signaling in Breast Cancer. Cell Reports, 2014, 8, 1077-1092.	6.4	122
10	Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma. Cancer Discovery, 2020, 10, 440-459.	9.4	103
11	Targeted fibrillar nanocarbon RNAi treatment of acute kidney injury. Science Translational Medicine, 2016, 8, 331ra39.	12.4	88
12	Rejection of immunogenic tumor clones is limited by clonal fraction. ELife, 2018, 7, .	6.0	88
13	Efficient 1-Step Radiolabeling of Monoclonal Antibodies to High Specific Activity with ²²⁵Ac for Î±-Particle Radioimmunotherapy of Cancer. Journal of Nuclear Medicine, 2014, 55, 1492-1498.	5.0	73
14	Banning carbon nanotubes would be scientifically unjustified and damaging to innovation. Nature Nanotechnology, 2020, 15, 164-166.	31.5	69
15	A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens. Journal of Clinical Investigation, 2017, 127, 2705-2718.	8.2	63
16	Carbon nanotubes as vaccine scaffolds. Advanced Drug Delivery Reviews, 2013, 65, 2016-2022.	13.7	62
17	Familial Alzheimer Disease Presenilin-1 Mutations Alter the Active Site Conformation of Î³-secretase. Journal of Biological Chemistry, 2012, 287, 17288-17296.	3.4	58
18	A TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR-ABL+ leukemias. Blood, 2014, 123, 3296-3304.	1.4	52

#	Article	IF	Citations
19	Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA. Nature Medicine, 2022, 28, 946-957.	30.7	50
20	Structure of a TCR-Mimic Antibody with Target Predicts Pharmacogenetics. Journal of Molecular Biology, 2016, 428, 194-205.	4.2	48
21	A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analogue Peptide Vaccine, After Multimodality Therapy for Patients with Malignant Pleural Mesothelioma. Clinical Cancer Research, 2017, 23, 7483-7489.	7.0	48
22	Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma. Oncotarget, 2017, 8, 14017-14028.	1.8	48
23	Therapeutic Efficacy of an Fc-Enhanced TCR-like Antibody to the Intracellular WT1 Oncoprotein. Clinical Cancer Research, 2014, 20, 4036-4046.	7.0	46
24	Opportunities and challenges for TCR mimic antibodies in cancer therapy. Expert Opinion on Biological Therapy, 2016, 16, 979-987.	3.1	45
25	Murine and humanized constructs of monoclonal antibody m195 (anti-cd33) for the therapy of acute myelogenous leukemia. Cancer, 1994, 73, 1049-1056.	4.1	43
26	Phase I Trial of Targeted Alpha-Particle Therapy with Actinium-225 (225Ac)-Lintuzumab and Low-Dose Cytarabine (LDAC) in Patients Age 60 or Older with Untreated Acute Myeloid Leukemia (AML). Blood, 2016, 128, 4050-4050.	1.4	43
27	A phase I study of anti-GD3 ganglioside monoclonal antibody R24 and recombinant human macrophage-colony stimulating factor in patients with metastatic melanoma. Cancer, 1995, 75, 2251-2257.	4.1	42
28	Deconvoluting hepatic processing of carbon nanotubes. Nature Communications, 2016, 7, 12343.	12.8	42
29	ALK and RET Inhibitors Promote HLA Class I Antigen Presentation and Unmask New Antigens within the Tumor Immunopeptidome. Cancer Immunology Research, 2019, 7, 1984-1997.	3.4	39
30	Engineering CAR-T cells to activate small-molecule drugs in situ. Nature Chemical Biology, 2022, 18, 216-225.	8.0	39
31	Adoptive transfer of unselected or leukemia-reactive T-cells in the treatment of relapse following allogeneic hematopoietic cell transplantation. Seminars in Immunology, 2010, 22, 162-172.	5.6	31
32	Encapsulation of Î±-Particleâ€“Emitting ²²⁵Ac³⁺ Ions Within Carbon Nanotubes. Journal of Nuclear Medicine, 2015, 56, 897-900.	5.0	31
33	Vascular Targeted Radioimmunotherapy for the Treatment of Glioblastoma. Journal of Nuclear Medicine, 2016, 57, 1576-1582.	5.0	30
34	Advances in the clinical translation of nanotechnology. Current Opinion in Biotechnology, 2017, 46, 66-73.	6.6	30
35	Phase I Trial of the Targeted Alpha-Particle Nano-Generator Actinium-225 (225Ac)-Lintuzumab (Anti-CD33; HuM195) in Acute Myeloid Leukemia (AML). Blood, 2011, 118, 768-768.	1.4	27
36	Alpha radioimmunotherapy using ²²⁵Ac-proteus-DOTA for solid tumors - safety at curative doses. Theranostics, 2020, 10, 11359-11375.	10.0	26

#	Article	IF	Citations
37	Remodeling the Vascular Microenvironment of Glioblastoma with Î±-Particles. Journal of Nuclear Medicine, 2016, 57, 1771-1777.	5.0	25
38	Identification of the Targets of T-cell Receptor Therapeutic Agents and Cells by Use of a High-Throughput Genetic Platform. Cancer Immunology Research, 2020, 8, 672-684.	3.4	25
39	An immunogenic WT1-derived peptide that induces T cell response in the context of HLA-A*02:01 and HLA-A*24:02 molecules. OncoImmunology, 2017, 6, e1252895.	4.6	20
40	Neutral glycosphingolipid expression in B-cell neoplasms. International Journal of Cancer, 1991, 49, 837-845.	5.1	19
41	Depleting T regulatory cells by targeting intracellular Foxp3 with a TCR mimic antibody. OncoImmunology, 2019, 8, e1570778.	4.6	19
42	Empirical and Rational Design of T Cell Receptor-Based Immunotherapies. Frontiers in Immunology, 2020, 11, 585385.	4.8	19
43	Solving an MHC alleleâ€“specific bias in the reported immunopeptidome. JCI Insight, 2020, 5, .	5.0	19
44	Carbon nanotubes exhibit fibrillar pharmacology in primates. PLoS ONE, 2017, 12, e0183902.	2.5	18
45	Targeted Cellular Micropharmacies: Cells Engineered for Localized Drug Delivery. Cancers, 2020, 12, 2175.	3.7	17
46	Low-dose CDK4/6 inhibitors induce presentation of pathway specific MHC ligands as potential targets for cancer immunotherapy. OncoImmunology, 2021, 10, 1916243.	4.6	15
47	PET-based compartmental modeling of 124I-A33 antibody: quantitative characterization of patient-specific tumor targeting in colorectal cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1700-1706.	6.4	13
48	A Genomic Profile of Local Immunity in the Melanoma Microenvironment Following Treatment with Î± Particle-Emitting Ultrasmall Silica Nanoparticles. Cancer Biotherapy and Radiopharmaceuticals, 2020, 35, 459-473.	1.0	13
49	Sequential Therapy with Cytarabine and Bismuth-213 (213Bi)-Labeled-HuM195 (Anti-CD33) for Acute Myeloid Leukemia (AML).. Blood, 2004, 104, 1790-1790.	1.4	12
50	Tumor-associated antigen PRAME exhibits dualistic functions that are targetable in diffuse large B cell lymphoma. Journal of Clinical Investigation, 2022, 132, .	8.2	12
51	Incorporation of bacterial immunoevasins to protect cell therapies from host antibody-mediated immune rejection. Molecular Therapy, 2021, 29, 3398-3409.	8.2	10
52	A TCR mimic CAR T cell specific for NDC80 is broadly reactive with solid tumors and hematologic malignancies. Blood, 2022, 140, 861-874.	1.4	10
53	Fibrillar pharmacology of functionalized nanocellulose. Scientific Reports, 2021, 11, 157.	3.3	8
54	Phase I Trial of Targeted Alpha-Particle Immunotherapy with Actinium-225 (225Ac)-Lintuzumab (Anti-CD33) and Low-Dose Cytarabine (LDAC) in Older Patients with Untreated Acute Myeloid Leukemia (AML). Blood, 2015, 126, 3794-3794.	1.4	8

#	Article	IF	Citations
55	A TCR mimic monoclonal antibody reactive with the â€œpublicâ€•phospho-neoantigen pIRS2/HLA-A*02:01 complex. JCI Insight, 2022, 7, .	5.0	8
56	CAR Chase: Where Do Engineered Cells Go in Humans?. Frontiers in Oncology, 2020, 10, 577773.	2.8	7
57	Impact of tumor heterogeneity and microenvironment in identifying neoantigens in a patient with ovarian cancer. Cancer Immunology, Immunotherapy, 2021, 70, 1189-1202.	4.2	7
58	Fibrillous Carbon Nanotube: An Unexpected Journey. Critical Reviews in Oncogenesis, 2014, 19, 261-268.	0.4	7
59	Unmasking the suppressed immunopeptidome of EZH2-mutated diffuse large B-cell lymphomas through combination drug treatment. Blood Advances, 2022, 6, 4107-4121.	5.2	7
60	Engineered Cells as a Test Platform for Radiohaptens in Pretargeted Imaging and Radioimmunotherapy Applications. Bioconjugate Chemistry, 2021, 32, 649-654.	3.6	6
61	A Therapeutic TCR Mimic Monoclonal Antibody for Intracellular PRAME Protein in Leukemias. Blood, 2015, 126, 2527-2527.	1.4	5
62	Hematology: The Biological Therapy of Acute and Chronic Leukemia. Cancer Investigation, 1997, 15, 342-352.	1.3	4
63	Mechanisms of leukemia resistance to antibody dependent cellular cytotoxicity. OncoImmunology, 2016, 5, e1211221.	4.6	4
64	A TCR mimic monoclonal antibody for the HPV-16 E7-epitope p11-19/HLA-A*02:01 complex. PLoS ONE, 2022, 17, e0265534.	2.5	4
65	The effects of amine-modified single-walled carbon nanotubes on the mouse microbiota. International Journal of Nanomedicine, 2018, Volume 13, 5275-5286.	6.7	2
66	An input-controlled model system for identification of MHC bound peptides enabling laboratory comparisons of immunopeptidome experiments. Journal of Proteomics, 2020, 228, 103921.	2.4	2
67	Epigenetic Drug Treatment Induces Presentation of New Class of Non-Exonic, Cryptic Neoantigens in Acute Myeloid Leukemia Cells. Blood, 2018, 132, 2717-2717.	1.4	2
68	Photo-Reactive and Non-Natural Amino Acid Epitopes of Human WT1 Enhance Immunogenicity and Allow Kinetic Study of Antigen Processing.. Blood, 2007, 110, 2311-2311.	1.4	1
69	Phase II Trial of WT1 Analog Peptide Vaccine in Patients with Acute Myeloid Leukemia (AML) in Complete Remission (CR). Blood, 2012, 120, 3624-3624.	1.4	1
70	Aerobic Glycolysis Predicts Outcome in Early Chronic Lymphocytic Leukemia.. Blood, 2012, 120, 2482-2482.	1.4	1
71	A TCR Mimic Antibody-Directed CAR T Cell Specific for Intracellular NDC80 Is Broadly Cancer Reactive and Displays High Activity Against Hematological Malignancies. Blood, 2020, 136, 20-21.	1.4	1
72	Generating Human Immune Responses to Mutations in Bcr-Abl Kinase Selected by Imatinib.. Blood, 2004, 104, 4689-4689.	1.4	0

#	Article	IF	Citations
73	Remodeling Specific Immunity by Use of MHC-Tetramers Distinguishes Graft-Versus-Tumor Activity from Graft-Versus-Host-Disease.. Blood, 2005, 106, 1300-1300.	1.4	0
74	Generation of Specific Human CD8+ T Cell Responses to the Myeloproliferative Disorder Associated V617F Mutated JAK2 Kinase by Use of Analog Peptide Vaccine Candidates.. Blood, 2005, 106, 3512-3512.	1.4	0
75	CD4+ Peptide Epitopes from the WT1 Oncoprotein Stimulate CD4+ and CD8+ T Cells That Recognize and Kill Leukemia and Solid Tumor Cells.. Blood, 2006, 108, 3706-3706.	1.4	0
76	Multivalent DNA Aptamer-Based Therapeutic Agents for Lymphoma and Leukemia.. Blood, 2009, 114, 2711-2711.	1.4	0
77	Elevated Mitochondrial Membrane Potential in CLL Cells Is Associated with a more aggressive Natural History. Blood, 2011, 118, 1765-1765.	1.4	0
78	A Cytotoxic Human Monoclonal Antibody Recognizing Cell Surface WT1 Peptide/HLA-A2 Complexes. Blood, 2011, 118, 1677-1677.	1.4	0
79	Therapeutic Efficacy and Cure Of Sensitive and T315I Pan-Resistant Human Ph+ Leukemia In Mice Using a TCR-Like Antibody To WT1/HLA-A0201 Alone, Or In Combination With Tyrosine Kinase Inhibitors. Blood, 2013, 122, 855-855.	1.4	0
80	Dual Inhibition of Histone Deacetylases and Phosphoinositide 3-Kinase Enhances Therapeutic Activity Against B Cell Lymphoma. Blood, 2016, 128, 293-293.	1.4	0
81	Immune surveillance of leukemia?. Haematologica, 2005, 90, 1297B.	3.5	0